

1 Persistent humoral immunity in children and adolescents throughout
2 the COVID-19 pandemic (June 2020 to July 2022): a prospective school-
3 based cohort study (Ciao Corona) in Switzerland

4
5 Alessia Raineri ^{1*}, Thomas Radtke ¹, Sonja Rueegg ¹, Sarah R. Haile ¹, Dominik Menges ¹, Tala
6 Ballouz ¹, Agne Ulyte ¹, Jan Fehr ¹, Daniel L. Cornejo ¹, Giuseppe Pantaleo ², Céline Pellaton ²,
7 Craig Fenwick ², Milo A. Puhan ¹, Susi Kriemler ^{1#}

8 * first authorship

9 # last authorship

10 ¹ Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Hirschengraben 84,
11 8001 Zürich, Switzerland

12 ² Service of Immunology and Allergy, Lausanne University Hospital (CHUV), University of Lausanne
13 (UNIL), Lausanne, Switzerland

14

15 Total word count: 4255

16

17 **Corresponding author:**

18 Susi Kriemler

19 Tel: +41 79 217 19 87

20 susi.kriemlerwiget@uzh.ch

21 Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich,

22 Hirschengraben 84

23 8001 Zürich, Switzerland

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Abstract

25 **Objectives** To assess the longitudinal development of humoral immunity in children and
26 adolescents during the COVID-19 pandemic, with a particular focus on how anti-spike IgG
27 antibodies and neutralising response changed during the first Omicron peak (December 2021
28 to May 2022).

29

30 **Design** Prospective school-based study during the COVID-19 pandemic (June 2020 to July
31 2022) including five testing rounds with corresponding cross-sectional cohorts and a
32 longitudinal cohort who participated in at least four rounds.

33

34 **Setting** 55 randomly selected schools in the Canton of Zurich, Switzerland.

35

36 **Participants** Between 1875 to 2500 children and adolescents per testing round and 751 in the
37 longitudinal cohort.

38

39 **Main outcome measures** Development of SARS-CoV-2 seroprevalence, anti-spike IgG
40 antibodies and neutralising antibody response over time, persistence of antibodies and
41 variation of antibody levels in individuals only infected, vaccinated or with hybrid immunity
42 during the early Omicron period.

43

44 **Results** By July 2022 96.9% (95% credible interval [CrI] 95.2 to 98.1%) of children and
45 adolescents had anti-spike IgG antibodies against SARS-CoV-2. The substantial increase in
46 seroprevalence during the first peak of the Omicron wave was largely driven by primary

47 infections in mostly unvaccinated children under the age of 12 (28.4% [95% CrI 24.2 to 33.2%]
48 in December 2021, to 95.7% [95% CrI 93.4 to 97.4%] in July 2022). This stands in contrast to
49 adolescents aged 12 years and older (69.4% [95% CrI 64.0 to 75.4%] in December 2021 to
50 98.4% [95% CrI 97.3 to 99.2%] in July 2022), who were eligible for vaccination since June 2021.
51 Children and adolescents with hybrid immunity or immunity from vaccination had high anti-
52 spike IgG titres (median Mean Fluorescence Intensity (MFI) ratio of 136.2 [Inter Quartile Range
53 [IQR]: 121.9 to 154.3] and 127.6 [IQR: 114.1 to 151.0]) and strong neutralising responses (e.g.,
54 anti-Omicron 98.9% [95% Confidence Interval [CI] 96.0 to 99.7%] and 81.6% [95% CI 74.9 to
55 86.9%]). Meanwhile, infected but unvaccinated children and adolescents had substantially
56 lower anti-spike IgG titres (median MFI ratio of 54.8 [IQR: 22.8 to 89.8]) and neutralising
57 responses (e.g., anti-Omicron 64.9% [95% CI 59.8 to 69.7%]).

58

59 **Conclusion** These findings show that the Omicron wave and the rollout of vaccines led to
60 almost 100% seropositivity and boosted anti-spike IgG titres and neutralising capacity in
61 children and adolescents. This was particularly driven by unvaccinated children (<12 years),
62 who became seropositive due to the highly infectious Omicron variant. Nevertheless, during
63 the entire study period parents of only one adolescent reported hospital stay of less than 24
64 hours related to a possible acute infection.

65

66 **Key words:** SARS-CoV-2, COVID-19, children, adolescents, school, longitudinal,
67 seroprevalence, humoral immunity, neutralising antibodies

68

69 Introduction

70 Monitoring the evolution of seroprevalence and assessing changes in humoral immunity
71 against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in children and
72 adolescents over time is important to understand how the pandemic evolved and to inform
73 public health measures including vaccination strategies as well as preventive measures at
74 school.

75 Several serological studies were conducted to detect SARS-CoV-2 infections in children and
76 adolescents and to determine seroprevalence at different times of the pandemic [1–6].
77 However, little is known about the development and persistence of those antibodies over time
78 as most studies were cross-sectional [1–5] and there is only limited data from longitudinal
79 studies assessing the humoral immunity in children and adolescents [7]. A systematic review
80 [7] reported persistence of cellular and humoral immunity in the pre-Omicron period lasting
81 for at least 10 to 12 months in children and adolescents. Meanwhile, few studies [8, 9] focused
82 on immune responses following Omicron, addressing neutralising activity and differentiating
83 between natural infection, vaccination, or both [10].

84 Many countries started to administer COVID-19 vaccines to children and adolescents in 2021
85 to 2022, after trials demonstrated the effectiveness of the COVID-19 vaccine against re-
86 infection [11, 12] or severe disease [13], and vaccination was approved by the Food and Drug
87 Administration and European Medicines Agency. In Switzerland, the COVID-19 vaccine was
88 available for adolescents aged 12 years and older by mid 2021 and for children aged 5 to 11
89 years in early 2022 [14].

90 In the beginning of 2022, the high incidence of SARS-CoV-2 infections in children and
91 adolescents due to the highly infectious Omicron variant despite the rollout of vaccines raised

92 concerns [15–17]. In that period, the coincidence of incomplete immunisation of youth and
93 the highly transmissible Omicron variant affected the evolution of seroprevalence and the
94 longitudinal development of the humoral immunity in children and adolescents.

95

96 In this observational school-based study, we aimed to assess the longitudinal development of
97 the humoral immunity in children and adolescents during the COVID-19 pandemic with a
98 particular focus on how anti-spike IgG antibodies and neutralising response changed during
99 the first Omicron peak in the context of (re-)infections, vaccinations, or their combination.

100

101 Method

102 **Study setting & design**

103 The Ciao Corona study is embedded in a nationally coordinated research network *Corona*
104 *Immunitas* in Switzerland [18]. The protocol of the study was registered prospectively
105 (ClinicalTrials.gov identifier: NCT04448717) [19], and seroprevalence results of the first four
106 Ciao Corona testing rounds can be found elsewhere [20–23]. This repeated cross-sectional
107 analysis is based on a prospective cohort study, using data from children and adolescents who
108 participated at multiple timepoints. The study took place in the canton of Zurich with its
109 around 1.52 million (18% of the Swiss population) ethnically and linguistically diverse
110 inhabitants and comprises rural as well as urban regions.

111 In March 2020, the first restrictions and preventive measures were announced from the Swiss
112 Federal Office of Public Health. Schools closed on 16 March 2020 and partially reopened on
113 10 May 2020, with a combination of in-person and online teaching. On 7 June 2020, schools
114 resumed usual in-person teaching with certain preventive measures (e.g., contact tracing
115 systems within schools, mandatory face mask for school personnel, distancing regulation).
116 Implementation of restrictions varied across schools. For adolescents of 12 years or older,
117 masks were mandatory starting from October 2020 and for children between 9 to 11 years
118 starting from January 2021. This was implemented due to an increase in the incidence of SARS-
119 CoV-2 infections, signaling a second pandemic wave. Throughout summer 2021, masks were
120 no longer mandatory for children and adolescents. However, they were reinstated for all
121 school children and adolescents from December 2021 to mid-February 2022 during the first
122 peak of the Omicron wave. Adolescents of 16 years or older were allowed to get vaccinated

123 starting from May 2021, adolescents between 12-15 years of age since mid-June 2021 and
124 children between 5 and 11 years of age from January 2022 [14].

125

126 **Population**

127 We randomly selected primary schools in the canton of Zurich and invited for each primary
128 school the secondary school that was the closest geographically. The number of invited
129 schools per district corresponded to the population size of the 12 districts. Out of 156 invited
130 schools, both public and private (around 10%), 55 schools agreed to participate. Classes were
131 randomly selected and stratified by school level: grades 1-2 (6 to 8 years old children) of lower
132 school level, grades 4-5 (9 to 11 years old children) of middle school level, and grades 7-9 (12
133 to 14 years old adolescents) of upper school level. All children and adolescents in the randomly
134 selected classes were eligible to participate in any of the testing rounds, irrespective of
135 whether they participated at baseline.

136

137 **Timeline of testing**

138 Venous blood samples were collected in five testing rounds. The first testing round (T1) was
139 performed in June/July 2020, the second (T2) in October/November 2020, the third (T3) in
140 March/April 2021, the fourth (T4) in November/December 2021 and the last fifth (T5) testing
141 round in June/July 2022. As shown in the study participant flow chart (Figure 1), we followed
142 corresponding repeated cross-sectional cohorts and a longitudinal cohort. The longitudinal
143 cohort consisted of children and adolescents participating in the last (T5) and at least three
144 previous testing rounds. In addition, we only included children and adolescents where the
145 seroconversion from one to the subsequent testing round was detectable.

146

147 **Serological testing and neutralisation assay**

148 In all five testing rounds, we visited children and adolescents in schools and collected venous
149 blood samples. To detect SARS-CoV-2 specific antibodies against spike and nucleocapsid
150 proteins we used the Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological
151 (SenASTrIS) test [24]. This Luminex assay measures the binding of IgG antibodies to the
152 trimeric SARS-CoV-2-spike and nucleocapsid proteins, obtaining the Mean Fluorescence
153 Intensity (MFI) ratio. Test results were considered seropositive if MFI ratios were equal to or
154 above the cutoff of 6 for both anti-spike IgG and anti-nucleocapsid IgG, based on which the
155 test has a 98% specificity and 99% sensitivity [24]. Test validation was performed in different
156 cohorts of pre-pandemic plasma of adults and children and SARS-CoV-2 infected people [24].
157 We used a cell-free and virus-free assay to detect SARS-CoV-2 neutralising antibodies against
158 the Wildtype SARS-CoV-2, Delta, and Omicron variants, by measuring the proportion of
159 antibodies preventing the binding of the angiotensin-converting enzyme 2 receptor to the
160 receptor binding domain of the trimer spike protein of the different SARS-CoV-2 variants [25].
161 Neutralising activity was quantified by the half maximal inhibitory concentration (IC50),
162 defining values of 50 or higher as positive [25].

163

164 **Questionnaire**

165 Online questionnaires were sent to participants at enrolment and repeatedly every 3 to 6
166 months over the duration of the study, collecting information on sociodemographic
167 characteristics, chronic conditions, and vaccination status. Vaccination status of children and

168 adolescents was either self-reported by children and adolescent on the day of testing in
169 schools or reported by parents/caregivers in online questionnaires.

170

171 **Groups of children and adolescent according to seropositivity and exposure status**

172 To assess the evolution of anti-spike IgG and neutralising antibody titres, we divided children
173 and adolescents from the longitudinal cohort into four groups according to their vaccination
174 and infection status. Children and adolescent never testing positive for anti-spike IgG were
175 categorised as *seronegative*, unvaccinated children and adolescent ever testing positive for
176 anti-spike IgG as *infected*, vaccinated children and adolescent testing negative for anti-spike
177 IgG prior to vaccination and never testing positive for anti-nucleocapsid IgG as *vaccinated*, and
178 children and adolescents testing seropositive before getting vaccinated, or were vaccinated
179 and tested positive for anti-nucleocapsid-IgG antibodies as *hybrid*.

180

181 **Statistical Analysis**

182 We performed descriptive analysis for participants' characteristics and antibody titres, by
183 reporting median (interquartile range) or count (percentage). Neutralising activity was
184 visualised using a log₁₀-transformation of scales. The Wilson method was used to calculate
185 95% confidence intervals (95% CI) of proportions [26]. We divided the study population into
186 children being younger than 12 years and adolescents of 12 years and older, based on
187 different vaccination policies for younger and older children and adolescents in Switzerland
188 [14].

189

190

191 We used Bayesian logistic regression to estimate the seroprevalence with 95% credible
192 intervals (95% CrI), using a model which accounts for the sensitivity and specificity of the SARS-
193 CoV-2 antibody test and the cohort's hierarchical structure. The Bayesian approach also
194 allowed to adjust for geographic district of the school, sex, and school grade of the child, and
195 included random effects for school levels (lower, upper, and middle). We used
196 poststratification weights to adjust for the population size of the particular school level and
197 the geographic district. Further details regarding the Bayesian model and weighting approach
198 can be found elsewhere [20].

199 Seroprevalence in the first three rounds (T1 to T3) was only referring to unvaccinated children
200 and adolescents since vaccination was only available since June 2021 (rounds T4-T5, see Figure
201 1). For T4 and T5, we conducted the analysis of seroprevalence for two groups: a) the
202 unvaccinated children and adolescents, and b) all participating children and adolescents.

203
204 To determine anti-spike IgG antibody decay times, we included all participants that
205 seroconverted at any testing round and of whom at least one follow-up serology was
206 performed. We excluded a) individuals who never tested seropositive for anti-spike IgG
207 antibody, b) who had no follow-up assessment after testing seropositive, c) those who were
208 vaccinated and d) those with potential reinfection, defined by the presence of anti-
209 nucleocapsid IgG or any increase in anti-spike IgG titres between two testing points. To
210 estimate the slope of antibody decay, we limited the data to the first seropositive result (the
211 closest and therefore likely highest MFI ratio after an infection) and all following timepoints,
212 and then realigned the time axis to begin at the first seropositive result for each individual as
213 done by others [27–29]. We then fit the univariable mixed-effects linear decay model for the

214 natural logarithm of the titres, with random intercepts for each participant. We used the
215 formula $(\ln(0.5)/\beta)$ to estimate the half-life (λ) in days, with β being the coefficient for time
216 deriving from the fitted model [27–29]. In the primary analysis, we estimated the anti-spike
217 IgG half-life in children and adolescents considering a time window of 365 days. Additionally,
218 we performed a sensitivity analysis, estimating the half-life over a time window of 220 days,
219 to ensure comparability with other published studies [8, 29–33]. Compared to other studies
220 that used even shorter time windows for estimating the half-life, we chose a time window of
221 220 days due to the timing of our testing rounds.

222

223 The analyses were performed with R programming language [34], including the RSTAN
224 package to fit the Bayesian models [35].

225


226

227 Results

228 1. Participant Characteristics

229 Throughout the study, we tested between 1876 and 2500 children and adolescents at each
230 testing round between June 2020 and July 2022. Figure 1 shows the flowchart of participating
231 schools and children and adolescents, and valid serological test results at each testing round.
232 Table 1 presents the baseline characteristics of the study population for the repeated cross-
233 sectional as well as for the longitudinal cohort (Supplementary Table 1 for more details on
234 chronic conditions). During the entire study period, three seropositive tested children and
235 adolescents reported hospital stays of less than 24 hours, of which one was possibly related
236 to an acute SARS-CoV-2 infection.

237



238

239 *Figure 1: Flowchart of participants. Newly enrolled children and adolescents did not participate in previous rounds.*

240 **Longitudinal cohort consists of children and adolescents participating in the last (T5) and at least three other testing rounds.*

241 *Yrs: years.*

242 **Table 1:** Baseline characteristics of the study population at each testing round. Yrs: years; a: Predominant variant of concern
 243 in Switzerland (>50% of circulating VOC in Switzerland); b) unique number of children and adolescents tested throughout the
 244 entire study period; c) number of children and adolescents tested per round; d: details on chronic conditions can be found in
 245 Supplement Table 1; e: grouped into <12 years and ≥12 years, since in Switzerland, adolescents ≥12 years of age could get
 246 vaccinated since mid-June 2021 and children between 5 and 11 years of age from January 2022; *median (interquartile range)

	T1	T2	T3	T4	T5
Timeframe of testing	Jun/Jul 2020	Oct/Nov 2020	Mar/Apr 2021	Nov/Dec 2021	Jun/Jul 2022
Predominant VOC^a	Wildtype	Wildtype	Alpha	Delta	Omicron
REPEATED CROSS-SECTIONAL COHORTS					
N unique^b	4251				
N tested^c	2473	2500	2450	1875	2105
Age* (yrs)	12 (6-17)	12 (7-17)	12 (7-17)	12 (7-17)	12 (7-18)
Sex (n, % male)	1197 (48%)	1211 (48%)	1165 (48%)	884 (47%)	990 (47%)
Age group					
<12yr	1450 (59%)	1298 (52%)	1144 (47%)	945 (50%)	1011 (48%)
≥12yr	1023 (41%)	1202 (48%)	1306 (53%)	930 (50%)	1094 (52%)
Existence of any chronic condition^d	546 (24%)	551 (24%)	536 (24%)	375 (23%)	412 (23%)
Vaccinated^e					
Overall	0	0	0	475/1876 (25%)	913/2105 (43%)
<12yr				0	283/1011 (28%)
≥12yr				475/930 (51%)	630/1094 (58%)
Questionnaires completed	2211 (89%)	2030 (81%)	1898 (77%)	1461 (78%)	1499 (71%)
LONGITUDINAL COHORT					
N unique^b	751				
N tested^c	695	725	738	722	751

Age* (yrs)	10 (6-15)	11 (7-16)	11 (7-16)	12 (8-17)	12 (8-17)
Sex (n, % male)	326 (43%)	341 (45%)	352 (47%)	341 (45%)	355 (47%)
School level					
<12yr	496 (71%)	492 (68%)	465 (63%)	377 (52%)	325 (43%)
≥12yr	199 (29%)	233 (32%)	273 (37%)	345 (48%)	426 (56%)
Chronic conditions^d	150 (21%)	161 (22%)	163 (22%)	159 (22%)	166 (23%)
Vaccinated					
Overall	0	0	0	184/722 (25%)	345/751 (46%)
<12yr				0	93/325 (29%)
≥12yr				184/345 (53%)	252/426 (59%)
Questionnaires completed	678 (90%)	647 (86%)	636 (85%)	610 (81%)	515 (69%)

247


248

249 **2. Repeated cross-sectional cohorts: Development of seroprevalence**

250 Figure 2 shows the seroprevalence of children and adolescents for each timepoint of testing.
251 Seroprevalence increased with each testing round in children and adolescents. Between T4
252 (Nov/Dec 2021) and T5 (Jun/Jul 2022) seroprevalence increased from 46.4% [95% credible
253 interval [CrI] 42.6-51.0%] to 96.9% [95% CrI 95.2-98.1%] in the overall study population and
254 from 31.3% [95% CrI 27.5-35.9%] to 95.8% [95% CrI 93.1-97.8%] among unvaccinated children
255 and adolescents. At T4, 25.3% of all children and adolescents were vaccinated (all of whom
256 were ≥ 12 yrs old), and at T5 43.4% (28% of children < 12 and 58% of adolescents ≥ 12 yrs old)
257 (see Table 1). When stratifying according to age, children below the age of 12 had a bigger
258 increase in seroprevalence between T4 and T5 (28.4% [95% CrI 24.2-33.2%] to 95.7% [95% CrI
259 93.4-97.4%], respectively) compared to adolescents of 12 years or more (69.4% [95% CrI 64.0-
260 75.4%] to 98.4% [95% CrI 97.3-99.2%], respectively) (Supplementary Table 2).

261

262



Seroprevalence*

unvaccinated	2.5%	5.6%	18.4%	31.3%	95.7%
overall				46.4%	96.9%

263

264 **Figure 2:** Evolution of the incidence of diagnosed SARS-CoV-2 infections in Switzerland and participants' seroprevalence from
 265 June 2020 to July 2022 using the cross-sectional cohort. Unvaccinated (light blue): unvaccinated children and adolescents
 266 across all 5 testing rounds; overall (dark blue): all children and adolescents participating; grey: predominant variant of concern
 267 in Switzerland (>50% of VOC circulating); *Seroprevalence was adjusted for school level, sex and district and test sensitivity
 268 and specificity.


269

270 3. Longitudinal Cohort: Trajectory of Anti-spike IgG Antibodies

271 Figure 3 shows the trajectory of anti-spike IgG antibodies using the longitudinal cohort (n =
272 386) excluding children and adolescents who never tested seropositive throughout all five
273 testing rounds (n= 37) and children and adolescents who seroconverted between T4 (Nov/Dec
274 2021) and T5 (Jun/Jul 2022) (n= 328). We categorised participants into four groups according
275 to their time of seroconversion, e.g., group 1 seroconverted before T1 (Jun/Jul 2020), group 2
276 seroconverted between T1 (Jun/Jul 2020) and T2 (Oct/Nov 2020), group 3 seroconverted
277 between T2 (Oct/Nov 2020) and T3 (Mar/Apr 2021), and group 4 seroconverted between T3
278 (Mar/Apr 2021) and T4 (Nov/Dec 2021). Anti-spike IgG antibodies remained detectable 6
279 months (T4 to T5: 99% (n= 208/210)), 12 months (T3 to T5: 99% (n= 113/114)), 18 months (T2
280 to T5: 93% (n= 28/30)) or 24 months (T1 to T5: 69% (n= 22/32)) in children and adolescents
281 after seroconversion, respectively. At T5, antibodies were still detectable in 99% (n= 384/386)
282 of all children and adolescents who seroconverted in any previous testing round
283 (Supplementary Figure 1 shows the MFI ratio converted to U/ml for Roche Elecsys anti-spike
284 IgG (WHO measure)). Anti-spike IgG titres increased with each testing round either by
285 reinfection, vaccination, or a combination of the two. A first increase in antibody titres
286 occurred between T3 and T4, coinciding with the introduction of vaccination in this age group
287 in Switzerland. The highest increase in titres, visualised by the most substantial colour change
288 in Figure 3, occurred between T4 and T5 when Omicron became the predominant VOC.

289 To better understand the duration of protection of infection-elicited antibodies in children
290 and adolescents, we evaluated the decay of anti-spike IgG. In a subpopulation of unvaccinated
291 children and adolescents, excluding all children and adolescents with potential reinfection

292 (detected by the presence of anti-nucleocapsid IgG or any increase in titres between two
293 testing points), we estimated the anti-spike IgG antibody half-life after following them up for
294 365 days. The anti-spike IgG half-life estimate for this primary analysis was 305 days [95% CI
295 263-363 days] (Supplementary Figure 2A). For the sensitivity analysis, considering a time
296 window of 220 days of follow up, the half-life estimate was 220 days [95% CI 170-312 days]
297 (Supplementary Figure 2B).



298

299 **Figure 3:** Individual trajectories of anti-spike IgG (anti-S IgG) mean fluorescence intensity (MFI) ratios over time separated by
300 first incidence of seropositive result ($n=386$). S-IgG+: Anti-Spike IgG positive MFI ratio; 1) S-IgG+ since T1: $n=32$; 2) S-IgG+
301 since T2: $n=30$; 3) S-IgG+ since T3: $n=114$; 4) S-IgG+ since T4: $n=210$. Children and adolescents seroconverting from T4 to T5
302 are not shown ($n=328$). Grey denotes seronegative anti-spike IgG result (≤ 6 U/ml). Colour denotes seropositive anti-spike IgG
303 result with different level titres. White colour indicates no blood result available. 37 children and adolescent tested
304 seronegative throughout all five testing rounds are not shown in the figure.

305

306

307


308 **4. Effect of the Omicron Wave**

309 **4.1. Longitudinal Cohort: Evolution of Anti-spike-IgG Antibodies**

310 Figure 4 shows the evolution of anti-spike IgG antibodies in groups of children and adolescents
311 separated by their serology and exposure status (i.e., seronegative, only infected, only
312 vaccinated, with hybrid immunity) at T4 (Nov/Dec 2021) and followed to T5 (Jun/Jul 2022).

313 This was the time when Omicron started to be the dominant VOC until the end of the first
314 large infection peak (Figure 2). Children and adolescents with hybrid immunity and who were
315 only vaccinated showed similarly high titre levels at T4 or T5, whereas infected but
316 unvaccinated children and adolescents showed considerably lower titres (Supplementary
317 Table 3 or 4). Yet, titres of all groups increased from T4 to T5 on average. The highest increase
318 in titres was seen in children and adolescents who were infected or seronegative in T4 and
319 received their first vaccination between T4 and T5. The smallest increase and the lowest titres
320 in T4 and T5 were observed in children and adolescents who were previously seronegative
321 and had their first SARS-CoV-2 infection (Supplementary Figure 3 and Supplementary Table 4
322 and 5 shows the MFI ratio converted to U/ml for Roche Elecsys anti-spike IgG (WHO measure)).

323
324 To detect and quantify infections or reinfections between T4 (Nov/Dec 2021) to T5 (Jun/Jul
325 2022), we tested anti-nucleocapsid IgG antibodies, as they were expressed only after a SARS-
326 CoV-2 infection and not after a vaccination. By mid 2022, more infections or reinfections
327 happened in unvaccinated children and adolescents (74%) than in vaccinated (27%), indicating
328 that vaccinated children and adolescents were likely better protected against an infection
329 (Supplementary Table 6).




330

331 **Figure 4:** Evolution of anti-spike IgG MFI ratios between T4 (Nov/Dec 2021) and T5 (June/July 2022) among seronegative,
 332 infected, vaccinated children and adolescents, and those with hybrid immunity at T4 shown as violin plots display mirrored
 333 density for each titre value (continuous distribution). For example, the top left panel represents 38 children and adolescents,
 334 who had median MFI titre of 107.1 in T4 (blue) and increased to median MFI titre of 133.1 in T5 (red)". Negative denotes
 335 seronegative at T4, Infected denotes seropositive but not yet vaccinated, Vaccinated denotes vaccinated participants, but
 336 negative in previous rounds and without evidence for anti-nucleocapsid IgG response. Children and adolescents with hybrid
 337 immunity were seropositive before getting vaccinated, or were vaccinated and tested positive for anti-nucleocapsid-IgG
 338 antibodies. Titre levels at T4 and at T5 are shown in blue and orange, respectively. Boxplots in panels show the median and
 339 interquartile range (IQR; whisker: 1.5 IQR). 60 children and adolescents are not shown in the figure (n=31 seronegative at T4
 340 and T5, n=29 no data at T4).

341

342 **4.2. Longitudinal Cohort: Evolution of the Neutralising Antibodies**

343 Figure 5 shows the development of neutralising antibodies against different SARS-CoV-2
344 variants (Wildtype, Delta, and Omicron) between T4 (Nov/Dec 2021) and T5 (Jun/Jul 2022).
345 We again separated participants into the four different groups according to their serology at
346 T4 and exposure status (i.e., seronegative, only infected, only vaccinated, or with hybrid
347 immunity). In general, neutralising activity increased in all groups between T4 and T5. The
348 neutralising response was proportionally higher, but comparable in those with hybrid
349 immunity and vaccination only (e.g., anti-Omicron at T5 98.9% [95% CI 96.0-99.7%] and 81.6%
350 [95% CI 74.9-86.9%], respectively, Supplementary Table 3), but lower in infected participants
351 (e.g., anti-Omicron at T5 64.9% [95% CI 59.8-69.7%]). The neutralising response at T5 was
352 higher for infected children and adolescents at T4 (Figure 5i) compared to seronegative
353 children and adolescents at T4 (Figure 5l, Supplementary Table 7 shows detailed test results).
354 Overall, neutralising response was highest against anti-Wildtype, followed by anti-Delta and
355 anti-Omicron, except in children and adolescent getting newly infected between T4 to T5
356 (Figure 5l), where anti-Omicron showed highest neutralising response, followed by anti-
357 Wildtype and anti-Delta.



358

359 **Figure 5:** Evolution of neutralising antibody half maximal inhibitory concentrations (IC₅₀) between T4 (Nov/Dec 2021) and T5
 360 (June/July 2022) among negative, infected, vaccinated children and adolescents, and those with hybrid immunity shown by
 361 violin plots display mirrored density for each NAB IC₅₀ value (continuous distribution). Negative denotes seronegative at T4,
 362 Infected denotes seropositive but not yet vaccinated, Vaccinated denotes vaccinated participants, but negative in previous
 363 rounds and without evidence for anti-nucleocapsid IgG response. Children and adolescents with hybrid immunity were
 364 seropositive before getting vaccinated, or were vaccinated and tested positive for anti-nucleocapsid IgG antibodies. Dotted
 365 line indicates NAB IC₅₀ value threshold (50) for half maximal inhibitory concentrations (IC₅₀) for neutralising activity. Children
 366 and adolescents with NAB IC₅₀ values above the threshold are assumed to have 50% or higher neutralisation capacity.
 367 Boxplots in panels show the median and interquartile range (IQR; whisker: 1.5 IQR). 60 children and adolescents are not shown
 368 in the figure (n=31 seronegative at T4 and T5, n=29 no data at T4).

369

370

371 Discussion

372 Throughout the course of the Ciao Corona study from June 2020 to July 2022, seroprevalence
373 increased with each further circulating VOC and uptake of vaccination in children and
374 adolescents. By July 2022 despite incomplete uptake of vaccination (58% in those ≥ 12 years,
375 28% in < 12 years), 96.9% [95% CrI 95.2-98.1%] of all children and adolescents had anti-spike
376 IgG antibodies against SARS-CoV-2 and most children under the age of 12 became seropositive
377 during the Omicron wave despite low vaccination uptake. Also, 93% of children and
378 adolescents who seroconverted early in the pandemic were persistently seropositive for up
379 to 18 months. Furthermore, vaccinated children and adolescents regardless of prior infection
380 had high to very high anti-spike IgG titres and proportionally higher neutralising response,
381 compared to unvaccinated but infected children and adolescents who showed lower SARS-
382 CoV-2 anti-spike IgG titres and neutralising responses.

383

384 We found a sharp increase in seroprevalence from 46.4% in T4 (Nov/Dec 2021) to 96.9% in T5
385 (Jun/Jul 2022), and anti-spike IgG antibody titre levels in seropositive participants were overall
386 higher at T5 compared to the beginning of the COVID-19 pandemic. While this is not surprising
387 for those receiving a vaccination, mostly adolescents of 12 years or more, it is remarkable that
388 also most without vaccination, i.e., children below the age of 12, became seropositive. This is
389 likely attributable to the overall high incidence of SARS-CoV-2 infections in the first half of
390 2022, where the highly transmissible Omicron variant that was able to evade both natural and
391 vaccine-induced immunity became dominant [15–17]. These findings are consistent with
392 other international studies in children and adolescents also reporting high seroprevalence and
393 titre levels by mid 2022 [4, 36–38]. However, seroprevalence is dependent on the course of

394 the pandemic, the circulating VOC, geographical region, and the uptake of vaccines, which is
395 why great variability in seroprevalence estimates were stated across different reports [39].

396

397 In our study, children and adolescents who seroconverted early in the COVID-19 pandemic,
398 were persistently seropositive for up to 18 months. Several studies reported on duration of
399 persistence of antibodies after a SARS-CoV-2 infection in children and adolescents. Some
400 studies reported that anti-spike IgG levels decrease within 4 to 6 months [40, 41], whereas
401 others showed that they remained detectable up to 9 to 18 months [9, 42, 43].

402 We likewise estimated that the anti-spike IgG half-life was 305 days in children and
403 adolescents overlooking a window of 365 days. The half-life estimate of our sensitivity analysis
404 using a time window of 220 days, was comparable to those of adults reporting between 145
405 to 238 days [8, 29–33]. Data on anti-spike IgG half-life in children and adolescents is limited
406 and results are controversial, ranging from faster decay of anti-spike IgG antibodies [8] to
407 similar [9] waning between children and adults. Thus, the estimate of half-life in our primary
408 analysis was higher than that of the sensitivity analysis and also higher than what has
409 previously been reported in adults. Several factors may explain these differences including the
410 unknown timepoint of infection, differential missingness due to immune function, as well as
411 differing assumptions made in the analyses. In particular, the sensitivity analysis with the
412 shorter time window covered only the early time after infection in which a faster decay of
413 antibodies takes place, while the primary analysis covered the period of a full year including
414 both the initial fast decline of antibodies followed by a period in which the decay was much
415 slower and steadier [8, 9].

416

417 Comparing the four groups, we found that anti-spike IgG antibody titres and neutralising
418 response were higher in children and adolescents with hybrid immunity or vaccination only
419 compared to only infected children and adolescents in July 2022. Neutralising capacity was
420 proportionally higher against all VOC in children and adolescents with hybrid immunity or who
421 were vaccinated compared to children and adolescents being only infected. We may have
422 underestimated the proportion of children and adolescents with hybrid immunity, considering
423 that anti-nucleocapsid IgG antibodies wane quickly and are also less expressed among
424 vaccinated individuals [44–46]. Therefore, we likely missed infections in early 2022 if anti-
425 nucleocapsid IgG were undetectable despite infection. However, since anti-spike IgG titres and
426 neutralisation were similar among those vaccinated or with hybrid immunity in comparison
427 with adults [37, 47–49], it is unlikely that this would have relevantly changed our findings.
428 Numerous studies demonstrate that adults with high antibody titres and neutralising activity
429 are protected against developing a severe course of SARS-CoV-2 disease [50–52]. Because only
430 one adolescent had a hospital stay of less than 24 hours likely related to a SARS-CoV-2
431 infection, it remains unclear whether the findings in adults of higher protection against severe
432 disease by vaccination and/or hybrid immunity can also be translated to children and
433 adolescents. A study to test this hypothesis in youth would require an extremely large
434 population-based study, as children and adolescents have a severe course of disease in less
435 than 1 %, far less than observed in adults [53, 54].

436

437 Our findings show that the overall humoral and population immunity is high in children and
438 adolescents in Switzerland. Policy makers and healthcare professionals in Switzerland closely
439 followed our study and considered these findings to guide their decisions on public health

440 recommendations and pandemic-related measures for children and adolescents. Repeated
441 discussions of our results with cantonal and national public health authorities contributed to
442 the decision of the Swiss Federal Office of Public Health that vaccination for youth below the
443 age of 16 was no longer recommended, and all preventive measures regarding children and
444 adolescents were lifted [55].

445
446 The Ciao Corona study is unique and one of few large longitudinal studies in youth [9, 37, 43].
447 We were able to reflect the time periods of the circulation of the major SARS-CoV-2 variants
448 (Wildtype, Alpha, Delta, and Omicron) during our five testing rounds between June 2020 and
449 July 2022. Also, serological testing allowed us to detect children and adolescents with
450 asymptomatic SARS-CoV-2 infection. With the longitudinal cohort we were able to assess
451 temporal changes in humoral activity during the COVID-19 pandemic. Furthermore, our study
452 is the first to show the proportion of children and adolescents with neutralising antibodies
453 based on a large school-based study.

454 However, some limitations need to be considered when interpreting the findings of this study.
455 First, the exact timing of SARS-CoV-2 infections in children and adolescents is not known in
456 sero-epidemiological studies. Thus, infection could have occurred days to months before a
457 participant tested seropositive in our study. Second, we may have misclassified some children
458 and adolescents when classifying them into the four different groups. Vaccination status was
459 self-reported by the study participants or their parents. This could have led to an over- or
460 underestimation of seroprevalence and differences in antibodies in the groups, due to recall
461 bias. Differentiation between children and adolescents with hybrid immunity or vaccination
462 only was based on the presence of SARS-CoV-2 anti-nucleocapsid IgG antibodies. Since the

463 anti-nucleocapsid IgG antibodies response is weaker when vaccinated (as shown in different
464 studies [44–46]), we likely underestimated children and adolescents with hybrid immunity.
465 Third, the estimation of anti-spike IgG half-life bears the limitations that the decay was
466 calculated using the first seropositive result and the time between our testing rounds varied
467 between 4 to 8 months. Due to the missing information on the exact timepoint of infection,
468 we set the peak at the first seropositive result to measure the decline in anti-spike IgG.
469 However, this approach may possibly underestimate maximum antibody titers and enhancing
470 variability of measured values. Consequently, we may have overestimated the half-life in
471 children and adolescents. Fourth, persistence of anti-spike IgG antibodies over 24 months in
472 69% of children and adolescents may be underestimated due to false positive serological
473 results at T1 (Jun/Jul 2020) when SARS-CoV-2 prevalence was low [56].

474

475

476 Conclusion:

477 In this study, we highlighted the importance of serological studies as a COVID-19 monitoring
478 tool and the development of humoral immunity in children and adolescents. Our findings
479 show that the Omicron wave and the rollout of vaccines led to almost 100% seropositivity and
480 boosted seroprevalence and anti-spike IgG antibody titres (by infection, reinfection, and/or
481 vaccination) as well as led to better neutralising capacity in children and adolescents.
482 Especially during the first peak of the Omicron wave, most unvaccinated children under the
483 age of 12 became seropositive compared to adolescents of 12 years and older, who had access
484 to vaccines since June 2021. Nevertheless, during the entire study period parents of three

485 children and adolescents reported a hospital stay of less than 24 hours, of which one was
486 possibly related to an acute SARS-CoV-2 infection.

487

488 **Authors Contributions:**

489 SK and MAP came up with the study idea. SK, MAP, TR, and JF developed the preliminary
490 design. SK, MAP, TR and AU established the study design and methodology. SK, AU, TR, SR,
491 SRH and AR performed participant recruitment, data collection and management. SRH, SR, AU
492 and AR conducted the data cleaning and the statistical analysis. GP, CF, CP and DLC devised
493 the serology analysis protocol and supervised, conducted, and assessed the serological
494 examinations. AR wrote the first draft of the manuscript. All authors were involved in the
495 interpretation of the findings, the review and authorisation of the manuscript for intellectual
496 accuracy. SK is the corresponding author and guarantor, assuming complete accountability for
497 the conducted research. Furthermore, SK had full access to the data, and made the final
498 decision to publish. The corresponding author (SK) attests that all listed authors meet
499 authorship criteria and that no others meeting the criteria have been omitted.

500

501

502 **Competing interests:**

503 All authors have completed the ICMJE uniform disclosure form at
504 www.icmje.org/coi_disclosure.pdf and declare: support from Swiss School of Public Health
505 (SSPH+), Swiss Federal Office of Public Health, private funders, funds of the cantons of
506 Switzerland (Vaud, Zurich, and Basel), institutional funds of universities, and University of
507 Zurich Foundation for the submitted work; no financial relationships with any organisations

508 that might have an interest in the submitted work in the previous three years; no other
509 relationships or activities that could appear to have influenced the submitted work.

510

511 **Funding:**

512 The Ciao Corona study was embedded in the nationally coordinated research network *Corona*
513 *Immunitas*, coordinated by the Swiss School of Public Health (SSPH+). The Ciao Corona study
514 was funded by fundraising of SSPH+, which included funds of the Swiss Federal Office of Public
515 Health as well as private funders (the SSPH+ ethical guidelines for funding will be considered),
516 by the Cantons of Switzerland (Vaud, Zurich, and Basel), by institutional funds of the
517 Universities. Additionally, the University of Zurich Foundation provided funding specific to this
518 study. The funder played no part in neither the planning and implementation of the study; nor
519 the collection, management, analysis, and interpretation of the data; nor the writing,
520 reviewing, and approving of the manuscript; nor the choice to submit the manuscript for
521 publication. All authors were able to fully access the output of the data analysis and take
522 responsibility for integrity and accuracy.

523

524

525 **Ethics approval:**

526 The Ethics Committee of the Canton Zurich, Switzerland, approved the study (2020-01336).
527 All study participants provided written informed consent prior to study enrolment.

528

529

530 **Transparency declaration**

531 The lead authors affirm that the manuscript is an honest, accurate, and transparent account
532 of the study being reported, no important aspects of the study have been omitted, and any
533 discrepancies from the study as originally planned and registered have been explained.

534

535

536 **Copyright:** The Corresponding Author has the right to grant on behalf of all authors and does
537 grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in
538 perpetuity, in all forms, formats and media (whether known now or created in the future), to
539 i) publish, reproduce, distribute, display and store the Contribution, ii) translate the
540 Contribution into other languages, create adaptations, reprints, include within collections and
541 create summaries, extracts and/or, abstracts of the Contribution, iii) create any other
542 derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the
543 Contribution, v) the inclusion of electronic links from the Contribution to third party material
544 where-ever it may be located; and, vi) licence any third party to do any or all of the above.

545

546

547 **References:**

- 548 [1] Szépfalusi Z, Schmidthaler K, Sieber J, et al. Lessons from low seroprevalence of SARS-
549 CoV-2 antibodies in schoolchildren: A cross-sectional study. *Pediatric Allergy and*
550 *Immunology* 2021; 32: 762–770.
- 551 [2] Oeser C, Whitaker H, Linley E, et al. Large increases in SARS-CoV-2 seropositivity in
552 children in England: Effects of the delta wave and vaccination. *Journal of Infection* 2022;
553 84: 418–467.
- 554 [3] Ladhani SN, Baawuah F, Beckmann J, et al. SARS-CoV-2 infection and transmission in
555 primary schools in England in June–December, 2020 (sKIDs): an active, prospective
556 surveillance study. *Lancet Child Adolesc Health* 2021; 5: 417–427.
- 557 [4] Ott R, Achenbach P, Ewald DA, et al. SARS-CoV-2 seroprevalence in preschool and
558 school-age children —population screening findings from January 2020 to June 2022.
559 *Dtsch Arztebl Int* 2022; 765–770.
- 560 [5] Sorg A-L, Bergfeld L, Jank M, et al. Cross-sectional seroprevalence surveys of SARS-CoV-
561 2 antibodies in children in Germany, June 2020 to May 2021. *Nat Commun* 2022; 13:
562 3128.
- 563 [6] Clarke KEN, Jones JM, Deng Y, et al. Seroprevalence of Infection-Induced SARS-CoV-2
564 Antibodies — United States, September 2021–February 2022. *MMWR Morb Mortal*
565 *Wkly Rep* 2022; 71: 606–608.
- 566 [7] Buonsenso D, Cusenza F, Passadore L, et al. Duration of immunity to SARS-CoV-2 in
567 children after natural infection or vaccination in the omicron and pre-omicron era: A
568 systematic review of clinical and immunological studies. *Front Immunol*; 13. Epub ahead
569 of print 11 January 2023. DOI: 10.3389/fimmu.2022.1024924.
- 570 [8] Lau EH, Hui DS, Tsang OT, et al. Long-term persistence of SARS-CoV-2 neutralizing
571 antibody responses after infection and estimates of the duration of protection.
572 *EClinicalMedicine* 2021; 41: 101174.
- 573 [9] Di Chiara C, Cantarutti A, Costenaro P, et al. Long-term Immune Response to SARS-CoV-
574 2 Infection Among Children and Adults After Mild Infection. *JAMA Netw Open* 2022; 5:
575 e2221616.
- 576 [10] Lin D-Y, Gu Y, Xu Y, et al. Effects of Vaccination and Previous Infection on Omicron
577 Infections in Children. *New England Journal of Medicine* 2022; 387: 1141–1143.

- 578 [11] Frenck RW, Klein NP, Kitchin N, et al. Safety, Immunogenicity, and Efficacy of the
579 BNT162b2 Covid-19 Vaccine in Adolescents. *New England Journal of Medicine* 2021;
580 385: 239–250.
- 581 [12] Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 Vaccine
582 in Children 5 to 11 Years of Age. *New England Journal of Medicine* 2022; 386: 35–46.
- 583 [13] Price AM, Olson SM, Newhams MM, et al. BNT162b2 Protection against the Omicron
584 Variant in Children and Adolescents. *New England Journal of Medicine* 2022; 386: 1899–
585 1909.
- 586 [14] News: Canton of Zurich. *Canton of Zurich*, <https://www.zh.ch/de/news-uebersicht.html?page=1&orderBy=new> (2023, accessed 13 March 2023).
- 588 [15] Lyngse FP, Mortensen LH, Denwood MJ, et al. Household transmission of the SARS-CoV-
589 2 Omicron variant in Denmark. *Nat Commun* 2022; 13: 5573.
- 590 [16] Shrestha LB, Foster C, Rawlinson W, et al. Evolution of the SARS-CoV-2 omicron variants
591 BA.1 to BA.5: Implications for immune escape and transmission. *Rev Med Virol*; 32.
592 Epub ahead of print 20 September 2022. DOI: 10.1002/rmv.2381.
- 593 [17] del Rio C, Omer SB, Malani PN. Winter of Omicron—The Evolving COVID-19 Pandemic.
594 *JAMA* 2022; 327: 319.
- 595 [18] West EA, Anker D, Amati R, et al. Corona Immunitas: study protocol of a nationwide
596 program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland.
597 *Int J Public Health* 2020; 65: 1529–1548.
- 598 [19] Ulyte A, Radtke T, Abela IA, et al. Seroprevalence and immunity of SARS-CoV-2 infection
599 in children and adolescents in schools in Switzerland: design for a longitudinal, school-
600 based prospective cohort study. *Int J Public Health* 2020; 65: 1549–1557.
- 601 [20] Ulyte A, Radtke T, Abela IA, et al. Variation in SARS-CoV-2 seroprevalence across
602 districts, schools and classes: baseline measurements from a cohort of primary and
603 secondary school children in Switzerland. *BMJ Open* 2021; 11: e047483.
- 604 [21] Ulyte A, Radtke T, Abela IA, et al. Clustering and longitudinal change in SARS-CoV-2
605 seroprevalence in school children in the canton of Zurich, Switzerland: prospective
606 cohort study of 55 schools. *BMJ* 2021; n616.

- 607 [22] Ulyte A, Radtke T, Abela IA, et al. Evolution of SARS-CoV-2 seroprevalence and clusters
608 in school children from June 2020 to April 2021: prospective cohort study Ciao Corona.
609 *Swiss Med Wkly* 2021; 151: w30092.
- 610 [23] Haile SR, Raineri A, Rueegg S, et al. Heterogeneous evolution of SARS-CoV-2
611 seroprevalence in school-age children. *Swiss Med Wkly* 2023; 153: 40035.
- 612 [24] Fenwick C, Croxatto A, Coste AT, et al. Changes in SARS-CoV-2 Spike versus
613 Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-
614 Based Seroprevalence Studies. *J Virol*; 95. Epub ahead of print 13 January 2021. DOI:
615 10.1128/JVI.01828-20.
- 616 [25] Fenwick C, Turelli P, Pellaton C, et al. A high-throughput cell- and virus-free assay shows
617 reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. *Sci*
618 *Transl Med*; 13. Epub ahead of print 4 August 2021. DOI: 10.1126/scitranslmed.abi8452.
- 619 [26] Brown LD, Cai TT, DasGupta A. Interval Estimation for a Binomial Proportion. *Statistical*
620 *Science* 2001; 16: 101–117.
- 621 [27] Whitcombe AL, McGregor R, Craigie A, et al. Comprehensive analysis of SARS-CoV-2
622 antibody dynamics in New Zealand. *Clin Transl Immunology*; 10. Epub ahead of print 14
623 January 2021. DOI: 10.1002/cti2.1261.
- 624 [28] Poehler E, Gibson L, Lustig A, et al. Estimating decay curves of neutralizing antibodies
625 to SARS-CoV-2 infection. *Math Med Biol* 2022; 39: 368–381.
- 626 [29] Menges D, Zens KD, Ballouz T, et al. Heterogenous humoral and cellular immune
627 responses with distinct trajectories post-SARS-CoV-2 infection in a population-based
628 cohort. *Nat Commun* 2022; 13: 4855.
- 629 [30] Wei J, Matthews PC, Stoesser N, et al. Anti-spike antibody response to natural SARS-
630 CoV-2 infection in the general population. *Nat Commun* 2021; 12: 6250.
- 631 [31] Cohen KW, Linderman SL, Moodie Z, et al. Longitudinal analysis shows durable and
632 broad immune memory after SARS-CoV-2 infection with persisting antibody responses
633 and memory B and T cells. *Cell Rep Med* 2021; 2: 100354.
- 634 [32] Wheatley AK, Juno JA, Wang JJ, et al. Evolution of immune responses to SARS-CoV-2 in
635 mild-moderate COVID-19. *Nat Commun* 2021; 12: 1162.

- 636 [33] Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up
637 to 8 months after infection. *Science (1979)*; 371. Epub ahead of print 5 February 2021.
638 DOI: 10.1126/science.abf4063.
- 639 [34] R Core Team. R: A Language and Environment for Statistical Computing, [https://www.R-](https://www.R-project.org/)
640 [project.org/](https://www.R-project.org/) (2022, accessed 13 March 2023).
- 641 [35] {Stan Development Team}. {RStan}: the {R} interface to {Stan}, <https://mc-stan.org/>
642 (accessed 13 March 2023).
- 643 [36] Oeser C, Whitaker H, Borrow R, et al. Following the Omicron wave, the majority of
644 children in England have evidence of previous COVID infection. *Journal of Infection*
645 2023; 86: 256–308.
- 646 [37] Skowronski DM, Kaweski SE, Irvine MA, et al. Serial cross-sectional estimation of
647 vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada.
648 *Can Med Assoc J* 2022; 194: E1599–E1609.
- 649 [38] Engels G, Hecker K, Forster J, et al. High seroprevalence of SARS-CoV-2 in preschool
650 children in July 2022. *Dtsch Arztebl Int*. Epub ahead of print 11 November 2022. DOI:
651 10.3238/arztebl.m2022.0345.
- 652 [39] Bergeri I, Whelan MG, Ware H, et al. Global SARS-CoV-2 seroprevalence from January
653 2020 to April 2022: A systematic review and meta-analysis of standardized population-
654 based studies. *PLoS Med* 2022; 19: e1004107.
- 655 [40] Leone V, Meisinger C, Temizel S, et al. Longitudinal change in SARS-CoV-2
656 seroprevalence in 3-to 16-year-old children: The Augsburg Plus study. *PLoS One* 2022;
657 17: e0272874.
- 658 [41] Bloise S, Marcellino A, Testa A, et al. Serum IgG levels in children 6 months after SARS-
659 CoV-2 infection and comparison with adults. *Eur J Pediatr* 2021; 180: 3335–3342.
- 660 [42] Renk H, Dulovic A, Seidel A, et al. Robust and durable serological response following
661 pediatric SARS-CoV-2 infection. *Nat Commun* 2022; 13: 128.
- 662 [43] Dunay GA, Barroso M, Woidy M, et al. Long-Term Antibody Response to SARS-CoV-2 in
663 Children. *J Clin Immunol* 2023; 43: 46–56.
- 664 [44] Allen N, Brady M, Carrion Martin AI, et al. Serological markers of SARS-CoV-2 infection;
665 anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection
666 in vaccinated individuals. *Journal of Infection* 2021; 83: e9–e10.

- 667 [45] Dhakal S, Yu T, Yin A, et al. Reconsideration of Antinucleocapsid IgG Antibody as a
668 Marker of SARS-CoV-2 Infection Postvaccination for Mild COVID-19 Patients. *Open*
669 *Forum Infect Dis*; 10. Epub ahead of print 4 January 2023. DOI: 10.1093/ofid/ofac677.
- 670 [46] Follmann D, Janes HE, Buhule OD, et al. Antinucleocapsid Antibodies After SARS-CoV-2
671 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273
672 COVID-19 Vaccine Efficacy Clinical Trial. *Ann Intern Med* 2022; 175: 1258–1265.
- 673 [47] Paniskaki K, Konik MJ, Anft M, et al. Superior humoral immunity in vaccinated SARS-
674 CoV-2 convalescence as compared to SARS-COV-2 infection or vaccination. *Front*
675 *Immunol*; 13. Epub ahead of print 31 October 2022. DOI:
676 10.3389/fimmu.2022.1031254.
- 677 [48] Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of Previous Infection and
678 Vaccination on Symptomatic Omicron Infections. *New England Journal of Medicine*
679 2022; 387: 21–34.
- 680 [49] Frei A, Kaufmann M, Amati R, et al. Development of hybrid immunity during a period of
681 high incidence of infections with Omicron subvariants: A prospective population based
682 multi-region cohort study. *medRxiv [Preprint]* 2022; 2022.10.14.22281076.
- 683 [50] Tenforde MW, Self WH, Naioti EA, et al. Sustained Effectiveness of Pfizer-BioNTech and
684 Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults —
685 United States, March–July 2021. *MMWR Morb Mortal Wkly Rep* 2021; 70: 1156–1162.
- 686 [51] Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe
687 Disease by Covid-19 Vaccines. *New England Journal of Medicine* 2022; 386: 340–350.
- 688 [52] Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-
689 2 and prevention of reinfection. *Nat Rev Immunol* 2021; 21: 395–404.
- 690 [53] Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the
691 proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2
692 infections. *Arch Dis Child* 2021; 106: 429–439.
- 693 [54] National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus
694 Disease 2019 (COVID-19) Treatment Guidelines. *National Institutes of Health*,
695 [https://www.covid19treatmentguidelines.nih.gov/management/clinical-](https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-children/special-considerations-in-children/)
696 [management-of-children/special-considerations-in-children/](https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-children/special-considerations-in-children/) (2023, accessed 13 April
697 2023).

- 698 [55] Federal Office of Public Health FOPH. Coronavirus: Vaccination. *The federal council*,
699 [https://www.bag.admin.ch/bag/en/home/krankheiten/ausbrueche-epidemien-
701 pandemien/aktuelle-ausbrueche-epidemien/novel-cov/impfen.html](https://www.bag.admin.ch/bag/en/home/krankheiten/ausbrueche-epidemien-
700 pandemien/aktuelle-ausbrueche-epidemien/novel-cov/impfen.html) (2023, accessed
702 15 March 2023).
- 703 [56] Altman DG, Bland JM. Statistics Notes: Diagnostic tests 2: predictive values. *BMJ* 1994;
704 309: 102–102.
- 705